Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal ...
中华网1 天
压倒性投票反对！FDA或考虑限制PD-1适应症，默沙东、BMS、百济神州 ...
BMS和默沙东方面则是主张维持现有的“全人群”适应症的标签。BMS的会议简报提到，不同药物的各项研究的评分方法和截断值存在差异，实施任何截断值都有可能让一部分患者失去获益的机会。
The American Journal of Managed Care2 天
Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...
The Pharma Letter2 天
FDA panel votes against broader use of checkpoint blockers
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...
Medpage Today on MSN3 天
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...
The Pharma Letter3 天
Miss for Merck’s favezelimab combo in colorectal cancer
Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint ...
Pharmaceutical Technology3 天
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.
Pharmabiz4 天
Merck’s Keytruda gets new approvals in Japan for certain patients with NSCLC and ...
Rahway, New Jersey Thursday, September 26, 2024, 09:00 Hrs [IST] ...
precisionmedicineonline4 天
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 ...
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...
muhc.ca4 天
New advances in lung cancer treatment
International clinical trial shows perioperative immunotherapy prolongs life in non-small-cell lung cancer patients.Positive ...
默沙东集团结直肠癌试验未达主要终点
结直肠癌仍是全球第三大常见癌症，其中微卫星稳定型疾病由于对免疫疗法反应有限而特别难以治疗。在美国，KEYTRUDA目前获批用于治疗经FDA批准的测试确定为不可切除或转移性高度微卫星不稳定 (MSI-H)或错配修复缺陷 (dMMR)的结直肠癌患者，但不适用于MSS mCRC。